Compare AZTA & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZTA | IOVA |
|---|---|---|
| Founded | 1978 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1996 | 2008 |
| Metric | AZTA | IOVA |
|---|---|---|
| Price | $18.60 | $4.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $40.60 | $9.00 |
| AVG Volume (30 Days) | 770.5K | ★ 15.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.52 | 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $593,821,000.00 | N/A |
| Revenue This Year | $6.99 | $47.74 |
| Revenue Next Year | $5.98 | $40.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.87 | $1.64 |
| 52 Week High | $41.73 | $5.63 |
| Indicator | AZTA | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 31.51 | 62.57 |
| Support Level | N/A | $2.03 |
| Resistance Level | $32.32 | $4.33 |
| Average True Range (ATR) | 1.45 | 0.21 |
| MACD | -0.43 | 0.06 |
| Stochastic Oscillator | 11.89 | 99.38 |
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.